Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Tumor vascular proteins as biomarkers in ovarian cancer.

Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA, Coukos G.

J Clin Oncol. 2007 Mar 1;25(7):852-61.

PMID:
17327606
2.

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.

Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V.

Mod Pathol. 2009 Feb;22(2):261-72. doi: 10.1038/modpathol.2008.174. Epub 2008 Oct 24.

3.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85. Epub 2007 Mar 6.

PMID:
17343903
4.

Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd.

Proteomics. 2002 Jan;2(1):76-84.

PMID:
11788994
5.

Gene expression patterns that characterize advanced stage serous ovarian cancers.

Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A.

J Soc Gynecol Investig. 2004 Jan;11(1):51-9.

PMID:
14706684
6.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

7.

Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.

Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A, Suri A.

Clin Cancer Res. 2007 Mar 1;13(5):1421-8.

8.

Overexpression of kallikrein 10 in epithelial ovarian carcinomas.

Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R.

Gynecol Oncol. 2003 Jul;90(1):44-50.

PMID:
12821340
9.

The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.

Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC.

Clin Cancer Res. 2003 Jan;9(1):44-51.

10.

Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo.

Su M, Feng YJ, Yao LQ, Cheng MJ, Xu CJ, Huang Y, Zhao YQ, Jiang H.

Int J Gynecol Cancer. 2008 May-Jun;18(3):476-86. Epub 2007 Jul 21.

PMID:
17645504
11.

Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.

Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ.

Oncogene. 2004 Oct 21;23(49):8065-77.

PMID:
15361855
12.

Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.

Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, Macgregor PF, Rosen B.

Oncol Rep. 2007 Dec;18(6):1347-56.

PMID:
17982616
13.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.

Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J.

Gynecol Oncol. 2007 Nov;107(2):266-73. Epub 2007 Aug 14.

PMID:
17698176
14.

Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N.

Int J Oncol. 2002 Nov;21(5):941-8.

PMID:
12370739
15.

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.

Buckanovich RJ, Sasaroli D, O'brien-Jenkins A, Botbyl J, Conejo-Garcia JR, Benencia F, Liotta LA, Gimotty PA, Coukos G.

Cancer Biol Ther. 2006 Jun;5(6):635-42. Epub 2006 Jun 9.

PMID:
16627987
16.

Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11.

PMID:
17346539
17.

Novel surface targets and serum biomarkers from the ovarian cancer vasculature.

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, Kougioumtzidou E, Katsaros D, Buckanovich R, Devarajan K, Sandaltzopoulos R, Godwin AK, Scholler N, Coukos G.

Cancer Biol Ther. 2011 Aug 1;12(3):169-80. Epub 2011 Aug 1.

18.

Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.

Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.

Prostate. 2008 Oct 1;68(14):1517-30. doi: 10.1002/pros.20803.

PMID:
18668517
19.

Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.

Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ.

Oncogene. 2003 Oct 16;22(46):7225-32.

PMID:
14562052
20.

[Screening and identification of ovarian carcinomas related genes].

Yue W, Sun LY, Li CH, Zhang LX, Pei XT.

Ai Zheng. 2004 Feb;23(2):141-5. Chinese.

PMID:
14960231

Supplemental Content

Support Center